Personalized Cancer Vaccines Show Promise in Late Stage Trial The latest developments in oncology demonstrate that the medical establishment's understanding of cancer is evolving rapidly.
Positive results from a late stage trial for an experimental personalized cancer vaccine developed by Merck and Moderna have sent shockwaves through the investment community, with Moderna's stock price soaring 100% in response.
This trial's focus on melanoma, a particularly aggressive form of skin cancer, sets it apart from other studies. Melanoma accounts for only about 1% of skin cancers but causes the majority of deaths among them.